SonarMD manages patients with conditions that have high variability in both cost and clinical outcomes. Currently deployed in patients with inflammatory bowel disease, the model is conducive to expansion in other chronic disease states with high variability. Through sophisticated patient engagement, targeted care management and specialty pharmacy optimization, SonarMD drives down costs and improves patient outcomes. SonarMD contracts with payers to manage this population of patients and works with existing in-network providers. For payers, it provides a holistic perspective on managing medical and drug costs for these patients. For providers, it provides the tools and resources needed to better engage and manage patients in a value-based care model and share in the cost savings.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
12/14/18 | $10,000,000 | Series A |
Arboretum Ventures BlueCross BlueShield Venture Partners | undisclosed |